Since the introduction of erlotinib and gefitinib, patients with metastatic EGFR positive lung cancer can be offered a therapeutic alternative that has proven its superiority over standard platinum-based chemotherapy2,.9 This evidence concerns the gene EGFR and lung carcinoma.